Thea Pharma

Executive Summary

Thea Pharma Inc., the U.S. subsidiary of the 150-year-old ophthalmology leader Laboratoires Théa, specializes in commercializing innovative eye care products. Since its founding in 2019, the company has focused on bringing the parent company's proven expertise and pipeline to the U.S. market, addressing high unmet needs in conditions like dry eye, glaucoma, and ocular inflammation. With a strong heritage in research and development, Thea Pharma is poised to capture significant market share through differentiated therapies, including preservative-free formulations and combination treatments. The company's strategy leverages established commercial infrastructure and specialist relationships, positioning it for steady growth in the competitive ophthalmic landscape.

Upcoming Catalysts (preview)

• Q3 2026FDA approval of preservative-free dry eye formulation60% success
• Q4 2026U.S. launch of glaucoma combination therapy50% success
• Q1 2027Positive Phase 3 data for anti-inflammatory ophthalmic solution55% success